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g r a p h i c a l a b s t r a c t

 Polycaprolactone and water-soluble

chitosan were combined in 3Dprinted drug delivery implant for
sustained-release.
 All the materials of the 3D-printed
implant are biocompatible,
biodegradable, low-toxic, costeffective, renewable, and the method
is simple and green.
 The preparation process was carried
out below 120 °C and solvent-free to
maintain the drug activity.
 Sustained release reached 99% and
lasted for 120 h by tailoring the drug
and chitosan content of the 3Dprinted implant.
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a b s t r a c t
Fused deposition molding (FDM) can complete most complex preparation of drug delivery implants to
meet the personalized needs of patients. However, the drug activity has strict requirements on processing
temperature and preparation method of filaments, the implant also has strict biocompatibility requirements for the materials. In this study, a drug delivery implant was prepared with good biocompatibility,
controlled and efficient drug release using FDM printing for personalized administration. Drug-loaded filaments were developed for FDM process by hot-melt extrusion (HME). Polycaprolactone was used as a
drug delivery carrier, and ibuprofen as the model drug. Notably, chitosan was dissolved to form controlled and efficient release channels. The printability, changes in physical and chemical properties during HME and FDM processes of the filament, and drug release behavior, mechanism and biocompatibility
of the implants were investigated. The results showed that the filament tensile strength decreased with
the increase of drug and chitosan content. No obvious degradation and chemical change occurred during
the whole process. The drug release efficiency could reach>99% and lasted for 120 h mainly via the diffusion - erosion mechanism. The viability of cells cultured for 24 h in 72 h, 100% implant extract was
75.3%.
Ó 2022 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).

Abbreviations: Polycaprolactone, PCL.
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1. Introduction

taken into accounts, thus the drug sustained-release performance
have not been explored [33,34]. Besides the selection of polymers,
it is necessary to prevent the blockage of the nozzle by large particulates during FDM process. An organic solvent is usually introduced to ensure that the mixture is more uniform for printing.
However, the addition of the solvent may affect the activity of
the drug [35,36].
This study aimed to prepare the drug-loaded PCL-CS filament
by hot-melt-extrusion (HME) process without adding the solvent, and then construct a drug delivery implant with a sustained drug release function using FDM process. Ibuprofen
(IBP), a non-steroidal anti-inflammatory drug, also possesses
analgesic and antipyretic activity. It can be used as the model
drug to manufacture unconventional and effective polymer drug
binding systems [37,38]. Water-soluble CS was added to the
insoluble matrix to form release channels and realize the controlled and efficient release of drugs. PCL was used as a drug
delivery carrier to obtain a low processing temperature and prevent reductions in drug activity. We investigated the printability,
physical and chemical changes during HME and FDM processes
of the filament, biocompatibility, drug release behavior and
mechanism of the implants.

In recent years, personalized drug delivery has generated a lot
of interest owing to the outstanding treatment results [1]. Personal
drug delivery meets the needs, characteristics, and preferences of
each patient, and hence exploring its administration methods is
of great significance [2]. A good drug administration route should
possess a relatively high transport efficiency of drugs, reduce the
toxicity and side effects of systemic or local administration, and
minimize the discomfort of patients during administration. The
commonly used drug delivery methods, including intravenous
injection, oral administration, makes the drug concentration in
blood rise rapidly in a short time, the concentration of the drug
taken orally also reduces greatly through the liver [3,4]. Therefore,
it is difficult to maintain the drug concentration in a therapeutically relevant range under the premise of one-time administration
through traditional drug delivery methods. While implants loaded
with active pharmaceutical ingredients (API) can accurately deliver
the drug to the target site and maintain the drug concentration,
improve drug delivery efficiency, reduce administration frequency
and improve compliance, ultimately improve the clinical results of
patients significantly [5]. In addition, the implant can be manufactured as a scaffold or catheter to support the damaged part, promote the rehabilitation of the injury [6–8]. However, it is difficult
to manufacture such novel drug implants with complex shapes
to fit the injury using conventional processing methods.
It is well recognized that three-dimensional (3D) printing can
address most manufacturing issues; of all the systems, fused deposition modeling (FDM) is one of the most widely used in healthcare
[5,9,10]. FDM is an extrusion-based ‘‘bottom-up” process that
involves the layer-by-layer addition of a material. It is flexible,
and customizable, and has a simple operation [11]. The equipment
of FDM mainly includes an actuating device, which allows the
polymer filament to proceed through the nozzle where the polymer is melted and then immediately cooled and deposited in the
plane or building model [12]. Polymeric materials with good biocompatibility have been widely used for in vitro cell cultures
[13,14], tissue engineering scaffolds [15,16], and drug delivery systems [17–19], which show potential for integration with 3Dprinted drug delivery implants.
In general, polymers with certain rigidities, strengths, flexibility, melt flow characteristics, and good crystallinity are suitable
for FDM process. Previously reported common sustained-release
polymer matrices include poly (vinyl alcohol) [20], ethylene–vinyl
acetate copolymers [21], polylactic acid [22] and KollidonÒVA64,
KollicoatÒ IR [23], Eudragit RL [24], (poly(lactic-co-glycolic acid)
[25], which can withstand the relatively high processing temperatures of FDM. Nevertheless, a risk of inactivating APIs at such high
processing temperatures exists, and the biocompatibility of materials should be considered. Thus, it is crucial to select a suitable
polymer matrix for preparing of drug delivery implants using
FDM. Polycaprolactone (PCL) is a polymer with a low melting
point. It is approved by the Food and Drug Administration (FDA)
as a bioabsorbable suture and drug delivery biomaterial due to
its nontoxicity, good biocompatibility, excellent flexibility, and
degradability [26,27], which make it suitable for use as a drug
delivery implant [27,28]. However, there are few studies on 3Dprinted PCL as drug sustained release carrier. Meanwhile, the drugs
are tightly embedded once added into the polymer matrix, making
their release through diffusion difficult [29]. To address this issue,
previous studies add some natural polymers, such as chitosan (CS),
hydroxypropyl cellulose and/or gelatin to the matrix as release
modifiers to render it flexible with controlled drug release [30–
32]. There are studies on adding CS to PCL for 3D printing. However, their research focuses on the mechanical properties, biological response of the final product. The effects of drugs were not

2. Materials and methods
2.1. Materials
Polycaprolactone (PCL, CAPA6800; Mn = 80,000, d = 3 mm,
melt index (MI) = 0.74 g/10 min (100 °C/2.16 kg)) was obtained
from Solvay Co., Ltd. (Guangdong, China). Ibuprofen (IBP) was
ordered from Beilang Biotechnology Co., Ltd. (Shanghai, China).
Chitosan (CS, Mv = 1000, Deacetylation degree  95%) was purchased from Gubei Biotechnology Co., Ltd. (Jiangsu, China).
Phosphate-buffered saline (PBS, XY-4308-1) solution with pH of
7.4 was acquired from Meilun Biotechnology Co., Ltd. (Dalian,
China). Minimum Essential Medium (MEM) and fetal bovine
serum were ordered from Hyclone (Logan, USA), trypsin and penicillin streptomycin were provided by Biosharp (Anhui, China),
L-929 cell, methyl thiazolyl tetrazolium (MTT) assay kit were
purchased from Beijing solarbio science & technology Co., Ltd.
(Beijing, China). Isopropanol was provided by Aladdin (Shanghai,
China). HDPE (5420 GA, melt index (MI) = 2.3 g/10 min
(190 °C/ 21.6 kg), 0.95 g/cm3) was purchased from the PetroChina
Co. Ltd. (Beijing, China).
2.2. Preparation of filaments
PCL, IBP, and CS were dried in a vacuum oven at 40 °C for 24 h to
remove moisture. The dried materials were weighed in different
proportions (Table 1) and mixed in a high-speed blender for
5 min. The mixture (300 g) was placed in a mini conical twinscrew extruder (JZSZ–10A, Wuhan Ruiming Experimental Instrument Manufacturing Co., Ltd., China) for HME and granulation.
The extrusion temperatures were set at 105 °C and 120 °C, and
the screw rotation speed was fixed at 25 rpm. After granulation,
the extrudates were dried under vacuum at 40 °C for 24 h. The
extrudates were passed through a single-screw extruder (the barrel temperature from the feeding position to the die was 100 °C,
105 °C, 105 °C, and 100 °C, and the screw rotation speed range
was 220 – 240 rpm). To precisely control the filament diameter,
a laser diameter gauge was used to monitor whether the filament
diameter was within the standard range in real time and adjust the
screw speed and pulling speed according to the feedback of the
measurements. The final filaments with diameters of about 1.75 ±
0.05 mm were extruded.
2
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and heated from 0 °C to 200 °C at a scanning rate of 10 °C/min.
The scanning rate was held at a constant temperature for 5 min
and then cooled to 0 °C at the same rate for 5 min to eliminate
the thermal history of samples. Then, the temperature was raised
to 200 °C at a rate of 10 °C/min, and the second DSC curve was
recorded. The voltage was 5 kV. Each experiment was repeated
three times to eliminate errors.
The thermal degradation behavior was also tested using a thermal gravimetric analyzer (TGA, Q50, TA, USA). The platinum crucible was first tared, then 6 mg sample was placed in the
platinum crucible. The ramp rate was 10 °C/min from 25 °C to
350 °C, under the protection of nitrogen purge gas (flow rate of
100 mL/min). The test was repeated three times.

Table 1
Composition of the filaments for HME.
Sample

PCL (%, w/w)

IBP (%, w/w)

CS (%, w/w)

PCL
PC5I4
PC5I8
PC5I12
PC5I16
PC5I20
PI12C4
PI12C8
PI12C12
PI12C16
PI12C20

100
91
87
83
79
75
84
80
76
72
68

–
4
8
12
16
20
12
12
12
12
12

–
5
5
5
5
5
4
8
12
16
20

2.6.3. X-ray diffraction (XRD)
X-ray diffraction (XRD) patterns of PCL, IBP, CS, and 3D-printed
implants were obtained using an X-ray diffractometer (XRD6100,
Shimadzu, Japan) with target radiation sources for Cu and Ni filters
under the following conditions: a scanning range (2 theta) of 5°–
50°, a scanning rate of 10°/min, a voltage of 40 kV, and a current
of 40 mA. Each experiment was repeated three times to eliminate
errors.

2.3. Mechanical properties of filaments
The tensile strength of the filaments with different amounts of
CS and IBP was determined using a universal testing machine
(RGT-20A, REGER, China) at room temperature. The filament sample size was determined using an electronic micrometer, with a
diameter d0 of 1.75 ± 0.05 mm, a length l0 of 140 mm, an original
standard distance of 60 mm, and a tensile speed of 50 mm/min.
Each experiment was repeated six times, and the mean value
was reported as the final result.

2.6.4. Micromorphology
3D-printed implants with an IBP content of 12 wt%, CS contents
of 4 wt%, 8 wt%, 12 wt%, 16 wt%, and 20 wt% were observed before
and after release. A scanning electron microscope (SEM; JSM7500F, JEOL, Japan) was used to observe the microstructure of
the fracture surfaces. The implant samples were brittle fractured
with liquid nitrogen, and the fracture surface was sprayed with
gold before SEM observations.

2.4. Dynamic rheological analysis of filaments
The dynamic rheological tests were carried out using a rotational rheometer (AR 2000ex, TA Instruments, UK) to determine
the viscoelastic properties of the filaments with different amounts
of IBP and CS. Standard ETC steel parallel plates (diameter = 25 m
m) were used with a 1 mm gap between the lower plate and the
upper plate. The oscillating frequency sweep was from 628.3 to
0.683 rad/s, the temperature was fixed at 120 °C, and a constant
strain amplitude of 0.01% was applied, which was well within
the linear viscoelastic region. Each experiment was repeated three
times, and the mean value was reported as the final result.

2.6.5. In vitro drug release
Implants with different structures and containing different
amounts of the drug and CS were tested to determine the drug
release behavior and mechanism in vitro, as described by Mao
et al. [39], with slight modifications. The samples were dried under
vacuum at 40 °C to a constant weight and accurately weighed.
Then, they were soaked in 100 mL of PBS buffer (pH = 7.4) in a
constant-temperature incubator with a shaking speed of 100 rpm
at 37 °C. The PBS buffer was changed within a specific time. The
concentration of IBP in PBS was measured with a double-beam
ultraviolet–visible spectrophotometer (TU-1901, PERSEE, China).
The drug concentration was measured at the characteristic absorption peak wavelength of 221 nm, and the standard curve was
drawn over a concentration range of 0–1000 lg/mL, in which the
drug concentration and absorbance showed a good linear relationship (R2 > 0.999). Each group comprised three samples, and all
samples were measured three times.

2.5. Implant preparation
A 3D model of the implant structure was designed using 3Ds
Max 2018 software and then exported as an STL file. 3D slicing
software was used to fill and slice the structure to obtain models
with different printing parameters. As shown in Fig. 1, the different
filaments prepared by HME were fed to fabricate the implants
using a commercially available desktop FDM printer (Gaonuoa001, Gaonuo-3d, China). The detail parameters of 3D printing
were listed in Table 2.
2.6. Characterization

2.6.6. Biocompatibility
The biocompatibility was evaluated using a cytotoxicity test.
According to the National Standard of China, GB/T 16886.5–2017,
Mouse fibroblast L-929 was cultured in vitro to test the potential
cytotoxicity of the 3D-printed implant. Firstly, the implant (PCL
80 wt%, CS 20 wt%) were immersed in Minimum Essential Medium
(MEM) containing 10% fetal bovine serum at 37 °C for 72 h, with
the ratio of sample to medium 1 g/ml. Besides a blank control, high
density polyethylene was set as the negative control, penicillin and
streptomycin was set as the positive control. After that, the cell
culture medium of L-929 in 96-well plates (104 cells per well) for
24 h was removed, replaced with 25%, 50%, 75%, 100% sample
extract, positive and negative control extract respectively, then
cultured in cell incubator (37 °C, 5% CO2, humidity > 90%) for
24 h. After the culture, the cell morphology and cell lysis were
observed under microscope, and the cell viability value of the test

2.6.1. Fourier-transform infrared spectrometry (FTIR) analysis
Fourier-transform infrared (FTIR) spectrometry (iS10, Nicolet,
USA) was used in the attenuated total reflectance mode in the
range of 700–4000 cm1 at a resolution of 4 cm1 with 32 scans.
3D-printed implants, pure PCL, CS and IBP were tested. Three
points were randomly selected on PCL, IBP, CS powder, and the
implants. The average value was taken as the final result.
2.6.2. Thermal analysis
The thermal behaviors of PCL, IBP, CS, and 3D-printed implants
were analyzed with a differential scanning calorimeter (DSC, Diamond, PerkinElmer, USA) equipped with a refrigerated cooling system. Under the protection of nitrogen purge gas (flow rate of
100 mL/min), 5 mg sample was placed in aluminum crucibles
3

Y. Yang, H. Wu, Q. Fu et al.

Materials & Design 214 (2022) 110394

Fig. 1. Schematic diagram of implant fabrication.

ity can be extruded smoothly by the FDM nozzle and solidified
instantly when printing each layer. As illustrated in Fig. 2c, and
2d, the presence of IBP reduced the complex viscosity and storage
modulus of PCL. When IBP with a relatively low molecular weight
was inserted into PCL chains, the distance between PCL chains
increased and the intermolecular forces weakened. The PCL chains
stretched and became prone to slip in the material, leading to a
plasticizing effect. Similar plasticizing effects of IBP on KollidonÒ
SR polymer [40] have also been reported. As shown in Fig. 2e,
and 2f, the presence of CS also reduced the complex viscosity
and storage modulus of PCL but to a lesser extent than IBP. This
might be explained as the difference in structures between IBP
and CS. The polarity of CS, with many hydroxyl groups, is greater
than that of PCL, which has more ether bonds and ester groups.
Therefore, based on the ‘‘like dissolves like” principle, the compatibility of IBP and PCL was better, and IBP was better dispersed in
the PCL matrix. As a result, the intermolecular forces were weakened, and the complex viscosity and storage modulus decreased
faster. Moreover, the complex viscosity of all composites decreased
upon increasing the frequency, showing shear thinning behavior,
which allowed the filament melt to pass through the nozzle
smoothly. In summary, the addition of IBP and CS improved the
plasticity of PCL; a low filler content must be used to meet the
demands of filaments during the FDM printing process. All filaments could be processed using FDM in this experiment.

Table 2
The optimized printing parameters used in FDM.
Processing variables
Temperature (°C)
Speed (mm/s)

Quality (mm)

Values
Printing nozzle temperature
Platform temperature
Printing speed
Traveling speed
Bottom printing speed
Outer wall printing speed
Inner wall printing speed
Layer height
Wall thickness
Bottom/top layer thickness
Fill density (%)
Extrusion capacity (%)
Double extrusion overlap
Minimum layer cooling time (s)

Nozzle diameter (mm)

120
0
60
100
20
30
60
0.2
0.8
0.6
20
100
0.15
5
0.8

article was measured by methyl thiazolyl tetrazolium (MTT) assay
method. There were six replicates in each group.

3. Results and discussion
3.1. Printability of the filaments
Filament with appropriate mechanical properties is the premise
of the FDM process. The thermoplastic filament was forced into the
heating nozzle through a pair of counter-rotating gears. Hence it
was necessary to ensure that the filament could pass through the
gears continuously and smoothly. Therefore, the filaments were
subjected to tensile tests to investigate their tensile strength. The
influence of the drug content on tensile strength is shown in
Fig. 2a. The tensile strength decreased when the drug content
was higher, indicating that the filament stiffness decreased linearly
upon plasticization by adding more IBP (y = - 0.541x + 15.167,
R2 = 0.9214). The addition of a drug weakened the intermolecular
forces of PCL, causing its tensile properties to decline. In the same
way, the tensile strength was inversely correlated with the CS content (y = -0.378x + 11.93, R2 = 0.9936), as displayed in Fig. 2b. As
the CS content increased, the stress concentration increased. CS
acted as a plasticizer that weakened the intermolecular forces of
the PCL matrix and decreased the degree of interchain entanglement, which ultimately decreased the tensile strength of the material. Furthermore, the gear motion in the process of feeding
filaments to the FDM printer was tested. The filaments possessed
relatively high rt and could be smoothly driven by the gears.
The rheological behavior of the filament also heavily influences
the FDM process. Only the filament with appropriate viscoelastic-

3.2. Changes before and after HME and FDM processes
The binding strength of the phases in filaments had a great
impact on the final properties of the printed composite structures,
and the binding strength was determined by the intermolecular
interactions of each phase. The FTIR spectra of the samples are
shown in Fig. 3a. The FTIR spectrum of PCL showed several bands
corresponding to the CH2 symmetric stretch at 2944 cm-1, CH2
asymmetric stretch at 2865 cm-1, carbonyl stretch at 1720 cm-1,
C-O and C-C stretch at 1290 cm-1, and C-O-C asymmetric stretch
at 1240 cm-1. The drug was represented by the carbonyl stretch
at 1710 cm-1. The benzene ring stretch appeared from 1600 cm-1
to 1450 cm-1, and the characteristic = C-H stretch of the benzene
ring was observed at 2960 cm-1. In terms of CS, the significant peak
from 3000 cm-1to 3500 cm-1represented the stretching vibration of
O-H and N-H, The peaks appeared at 2889 (-CH stretching) and
1659 cm-1 (amide I). In the 3D-printed implant spectrum, some
peaks shifted. A broad band from 3000 cm-1 to 2500 cm-1 appeared,
which indicated the formation of strong hydrogen bonds between
the unique carboxyl group of IBP and the hydroxyl group of PCL.
Additionally, the formation of hydrogen bonds homogenized the
electron cloud density, which reduced the frequency of the stretch.
4
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Fig. 2. Influence of (a) drug content and (b) CS content on tensile strength (rt) at the break of filaments. The relationship between frequency and (c and e) complex viscosity
(g*), (d and f) storage modulus (G 0 ) of filaments.

Fig. 3. (a) FTIR spectra of PCL, IBP, CS and 3D-printed implants. (b) DSC patterns of PCL, IBP, CS, and 3D-printed implants. (c) TG patterns of IBP, PCL, CS, and 3D-printed
implant. (d),(e) XRD patterns of PCL, IBP, CS, and 3D-printed implants. (f), (g), (h) SEM photograph of 3D-printed implants with an IBP loading of 12 wt% and a CS loading of
4 wt%, 12 wt%, and 20 wt%.

studies [41,42]. The peak of CS from 3000 cm-1 to 3500 cm-1 was
weakened, which might be due to the decomposition of hydroxyl
groups by heat treatment during FDM and HME process.
Beside the changes in the functional groups, the crystalline state
of the drug, CS, and PCL might change during the HME and FDM
processes. To verify crystallinities, the raw materials and composites were characterized using DSC. As shown in Fig. 3b, the melting
point of IBP was 80.2 °C, which demonstrated the presence of drug
crystals, consistent with a previous study by Chow [43]. In the CS
curve, two relatively smooth endothermic peaks appeared at

In the spectrum of the 3D-printed implant, the absorption frequency of C=O shifted from 1720 cm-1 to a lower wavenumber of
1710 cm-1, further demonstrating the formation of hydrogen
bonds. Moreover, no characteristic absorption peak of the drug
was observed in the infrared spectrum of the composite material,
and no obvious difference was found between the characteristic
peak of the drug and the matrix. This indicated that the addition
of the drug did not affect the chemical structure of the matrix,
and no new chemical bonds were formed during the HME and
FDM processes. IBP remained stable at 120 °C, as reported in recent
5

Y. Yang, H. Wu, Q. Fu et al.

Materials & Design 214 (2022) 110394

81.6 °C and 156.9 °C. The DSC curve of PCL showed an endothermic
peak at approximately 58.7 °C, representing the melting point of its
known semi-crystalline form. Differences in the thermal behavior
were found between the PCL loaded with IBP, CS, and raw materials. The ternary composite containing 20% IBP did not exhibit three
endothermic peaks, indicating that their crystalline states changed
during HME and printing, which revealed that IBP and CS transformed from crystalline into amorphous materials. The melting
point of PCL decreased to 48.2 °C because the addition of the drug
and CS played an important role in plasticizing the matrix. Both
molecules inserted into the PCL macromolecular chains reduced
the crystallinity and weakened the intermolecular forces of PCL.
In addition, hydrogen bonds were formed between the PCL chains
and the drug, which was also confirmed by the rheology and FTIR
results. Thus, the thermal processing window of PCL was
broadened.
XRD experiments were carried out to obtain the crystalline
structure information of as-received drug powders and PCL/IBP/
CS composites containing different amounts of IBP and CS so as
to investigate further the crystalline morphology of IBP and CS in
composites. The crystallization peaks of PCL and IBP appeared
between 10° and 40°, which were consistent with previous reports
[44,45]. Pure PCL, as a semi-crystalline material, displayed two
obvious characteristics. Bragg diffraction peaks at 2h values of
21.4° and 23.7°. These were respectively attributed to the (1 1 0)
and (2 0 0) lattice planes, indicating that PCL retained its semicrystalline state after extrusion and printing. The as-received drug
powders were confirmed to be stable crystalline, IBP with main
peaks at 12.3°, 16.7°, 19.04°, 20.1°, and 22.36° (Fig. 3d). The diffraction peak intensities of PCL in the composites markedly decreased
upon increasing the drug loading, indicating a lower crystallinity.
At the same time, an extra weak crystallization peak was observed
at 2h = 12.3°, which corresponded to the characteristic peaks of the
drug in the XRD diffractogram of the composite containing 8%
drug. The weak diffraction peak intensity of the drug in the composites tended to slightly increase as the drug content increased,
demonstrating the presence of a few drug crystals in the composites, while most of the crystalline forms of the drug were destroyed
during HME and printing. No peak shift was observed upon
increasing the drug loading, indicating that the melt processing
did not change the crystal structure of PCL. Compared with PCL,
CS is a weakly crystalline material present at less than 5% in the
composite materials; therefore, its diffraction peak was not
observed in the XRD patterns. Moreover, as shown in Fig. 3e, the
PCL diffraction peak decreased continuously upon increasing the
CS content. The presence of CS influenced the interactions between
PCL molecules, which affected the regular arrangement of PCL
molecules and reduced its crystallinity. The XRD diffractogram of
the composites containing different CS contents showed one characteristic peak of CS, indicating that CS might transform into an
amorphous state during HME and FDM.
The TG test was performed to verify the degradation through
the whole process. The result showed that under the highest temperature of 120 °C in HME and FDM process, the remaining weight
of PCL was 100%, the drug IBP was 99.48%, CS was 99.6% and the
final implant (PI12C12) was 99.92%. The onset temperature of
PCL was around 333 °C, IBP was 152 °C, CS was 178 °C and implant
was 191 °C. Which was far more than 120 °C. Therefore, it came to
the conclusion that no obvious degradation occurred in HME and
FDM process.
The morphology of the implant was observed using SEM to
visually analyze the dispersion of the drug and CS in the PCL
matrix. As shown in Fig. 3f, g, h, drug particles were embedded
in the PCL matrix, and no obvious agglomeration was detected at
a drug loading of 12%, indicating good interfacial adhesion and
compatibility between the IBP and PCL matrices. This might be

due to the effect of shear forces on the composites during HME
and FDM. In addition, the strong hydrogen bonds between IBP
and PCL also improved the interfacial compatibility to some
degree, as shown by the FTIR results. A slight local uplift was
observed on the surface upon increasing the CS content, but CS
particles were not observed. CS increased the roughness of the surface of the implant, but CS was uniformly distributed in the PCL
matrix because the single-screw extruder and printer sheared the
composite. The addition of CS also reduced the crystallinity of
the composite, and hence CS and PCL matrix were well fused.
3.3. Drug release behavior
A study of the release behavior of the implant is necessary for
its application. The structure of the implant greatly influenced
the release performance. Fig. 4a compared the accumulated release
over time of two structures as an example. Two different structures
(structure 1 and structure 2) with the same size, CS content of
12 wt%, and IBP content 12 wt% were printed. Both structure 1
and structure 2 had three layers, but structure 2 was interlaced
between two layers, and structure 1 was denser than structure 2.
The slope of the release line of structure 2 was higher, indicating
a faster release rate. The accumulative release from structure 2
increased from 43% to 62.3% compared with structure 1. This
was likely because structure 2 had a much higher relative specific
surface area, and the drug was more exposed to the PBS buffer
solution, which promoted a more complete and efficient release.
As a result, the drug release could be controlled by adjusting the
structure and shape of the implant, which could be easily realized
by 3D printing.
The influence of the drug content (4 wt% to 20 wt%) with structure 2 on in vitro dissolution is shown in Fig. 4b. The drug release
increased from 28% to 100% when the drug content increased from
4% to 20%. The dissolution of the drug introduced more release
channels in the PCL matrix, leading to complete drug release.
The influence of the CS content with structure 2 on the drug
release behavior is shown in Fig. 4c. The drug release increased
from 55% to 100% when the CS content increased from 4% to 20%.
With higher CS contents, both the rate and extent of drug release
increased because more release channels were formed, leading to
an easy and complete release of the drug. The change was obvious
from CS contents of 4 wt% to 12 wt%, but the accumulative release
rate did not obviously change upon increasing the CS content. This
might be due to the limited drug dosage, which led to the upper
limit of drug release. Too much CS affected the printability of the
filament, as described in Section 3.1. As a result, a proper amount
of CS should be added to form enough channels without destroying
the printing performance of the filament.
In summary, depending on the patients’ need, a controllable
accumulative release could be achieved at a specific time by changing the drug and CS contents and structures.
3.4. Drug release mechanism
When designing an implantable drug delivery device, it is necessary to focus on the mechanism(s) and hence the kinetics of
release of the desired drug. In order The in vitro drug release data
of 3D-printed implants were fitted by zero-order, first-order, and
Ritger-Peppas mathematical models to determine the drug release
mechanism. The correlation coefficient R2 was chosen as the reference to define the approximation accuracy of each model. As
shown in Table 3, the first-order and Ritger-Peppas models fit
the data better. The best fit was obtained with the first-order equation (R2 > 0.98 for all samples), indicating that diffusion is the predominant release mechanism of the drug. The Ritger-Peppas
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Fig. 4. Influence of (a) the structure, (b) drug content, and (c) CS content on the accumulative release over time.

Table 3
Drug release data fitted using dynamic models.

PI12C4
PI12C8
PI12C12
PI12C16
PI12C20

Zero order
Mt/M1=k0t + Q0

First order
In(1-Mt/M1) = -kt

Ritger -Peppas
Mt/M1=ktn

R2

R2

n

R2

0.9617
0.9044
0.8725
0.8970
0.9451

0.9848
0.9921
0.9986
0.9960
0.9910

0.45
0.63
0.62
0.57
0.49

0.9745
0.9584
0.9438
0.9243
0.8691

accompanied by the dissolution of some of the CS, which formed
a small number of pores on the surface. In the second stage, as time
went on, the drug on the surface of the implant diffused into the
solution, and more CS was exposed to the buffer solution, causing
further dissolution. This led to the formation of more pore channels
on the surface of the implant, and more drug was released through
these channels. At this time, the release method of the drug was a
combination of free diffusion and erosion. In the third stage, the
drug on the surface of the implant was nearly completely dissolved, and a large number of pores were formed due to the dissolution of a large amount of CS, so that the number of drug release
channels increased. As a result, the drug was mainly released
through the channels, and in this stage, the drug was mainly
released via an erosion mechanism.

equation showed that the drug release also proceeded via a
diffusion-erosion mechanism (0.45 < n < 0.89).
The SEM images further verified the drug release mechanism.
The surfaces of the printed implants before and after the release
are shown in Fig. 5. Taking the CS content of 12% as an example,
compared with the CS content of 4%, small channels were found
on the surface of the structures after implant soaking, as shown
in Fig. 5f, which were caused by the dissolution of water-soluble
CS. The number of channels increased upon increasing the CS content, which facilitated further drug release, leading to an improvement in the total drug release amount and efficiency. The drug was
released gradually, and CS eroded slowly. This observation was
consistent with the diffusion-erosion drug release mechanism
indicated by the data fitting with the Ritger -Peppas model. As
shown in Fig. 6, the drug on the surface of the implant rapidly dissolved in the buffer solution immediately after dipping the sample
into the release medium in the first stage. This was called the
‘‘burst effect”, which was explosive dissolution, and the drug was
mainly released via a diffusion mechanism in this stage. This was

3.5. Cytotoxicity of the implant
Implants are required to have good compatibility with human
body. Although PCL and CS are products with good biocompatibility,
7
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Fig. 5. SEM images of the surfaces of 3D-printed structures with different CS loadings before and after release: (a) 4 wt%, (d) 12 wt%, corresponding to (b), (e) and (c) and (f)
are the local amplification of (b) and (e) respectively.

Fig. 6. Schematic diagram of the drug release process.

Fig. 7. Morphology under optical microscope of (a) 25% implant extract; (b) 50% implant extract; (c) 75% implant extract; (d) 100% implant extract; (g) negative control: high
density polyethylene extract; (h) positive control: penicillin and streptomycin cultured L-929 cell and the blank control before (e) and after (f) culture.
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the HME and FDM processes may affect the biocompatibility of the
final products. Therefore, the cytotoxicity of the implant was
tested. As shown in Fig. 7, the cell morphology of the blank control
before and after culture and negative control was almost the same,
the cell in active control group changed greatly, indicating the
decrease of cell viability. In contrast, the cell morphology of the
implant group was basically intact after incubating the cells for
24 h, which should be attributed to the biocompatible materials
and the harmless processing methods. The MTT results also verified the biocompatibility of the implant, the cell viability value of
blank control and negative control was 100%, positive control
was 9.2. 25%, 50%, 75%, 100% implant extract was 94.37%, 87.4%,
84.0%, 75.3% (Table S1), respectively, showing a preferable
biocompatibility.
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In this study, a biocompatible, complex-shaped, sustained drug
release implant based on PCL and CS was achieved by FDM printing
without adding organic solvent. All the filament in the paper has
good printability. IBP and CS acted as plasticizers that weakened
the intermolecular forces of the PCL matrix and decreased the
degree of interchain entanglements, which ultimately decreased
the tensile strength of the material. This restricted the filler content of the filaments used in FDM printing. The changes in the filaments before and after HME and FDM processes were studied. The
FTIR results showed that strong hydrogen bonds were formed
between the unique carboxyl group of IBP and the hydroxyl group
of PCL, but no new chemical bonds were formed, together with
TGA results, indicating that the drug, CS, PCL, did not degrade during HME and FDM processes. The DSC and XRD results showed that
most of the crystalline structure of the drug was destroyed during
HME and FDM processes, and CS might have transformed into an
amorphous state. Both molecules inserted into the PCL macromolecular chains reduced the crystallinity of PCL, and the intermolecular forces of PCL were weakened. Thus, the thermal
processing window of PCL was broadened. The morphology was
observed using SEM, which showed that the interfacial adhesion
and compatibility between the drug and the PCL matrix were good.
Although CS increased the surface roughness of the implant, it was
well fused with the matrix and uniformly distributed. The release
behavior and the mechanism were explored, which showed that
the release extent and rate increased at higher CS and drug contents. Notably, controllable and sustained drug release over
120 h was achieved by adjusting the drug and CS contents, as well
as the printed structures. The release was well fitted by the firstorder and Ritger-Peppas models and verified by SEM. As a result,
the released mechanism was shown to be diffusion-erosion. The
biocompatibility was measured using MTT assay, the cell was basically intact after implant extract incubating for 24 h, the cell viability value of 100% implant extract was 75.3%, showing a preferable
biocompatibility. In conclusion, FDM printing made it possible for
implants with different structures and shapes and allowed the
drug release to be tailored to the time or dose. Hence, the filament
could be manufactured as an implant for controllable and efficient
sustained drug release in personalized administration. The sustained drug release implant was also expected to be used as scaffolds or catheters to support the wounds in human body, such as
bone tissue repair, facial plastic surgery.
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